PD-1 immunotherapy plus chemotherapy before and after gastric surgery
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and can consent to the study
- Your stomach or stomach–esophagus junction cancer has been newly diagnosed and is planned for surgical removal
- Your cancer scans show measurable spots that can be tracked (about 1 cm or larger)
- You are well enough for treatment (KPS score 80–100) and can receive chemotherapy
- You do not have spread to distant organs or return of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
This trial tests whether adding a short course of radiation to a combination of immunotherapy (PD-1 inhibitor) and chemotherapy (SOX) before surgery helps treat advanced stomach or GEJ cancer. It aims to see if the extra radiation makes the treatment more effective.
Hear when a new Locally Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.